Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,503,375.34. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

Shares of EW opened at $84.54 on Friday. The firm has a market capitalization of $48.68 billion, a P/E ratio of 48.59, a P/E/G ratio of 2.21 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a 50 day moving average price of $89.16 and a two-hundred day moving average price of $85.79. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on EW shares. UBS Group initiated coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective for the company. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Piper Sandler reissued an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EW. Rehmann Capital Advisory Group raised its stake in Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after buying an additional 130 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares during the period. Stephens Inc. AR boosted its holdings in shares of Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after buying an additional 144 shares during the period. Aspen Investment Management Inc grew its position in shares of Edwards Lifesciences by 1.5% during the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company’s stock valued at $885,000 after buying an additional 150 shares during the last quarter. Finally, NorthRock Partners LLC grew its position in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after buying an additional 153 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.